{"asset":{"id":"4b339c77-1cdc-4fe8-b9bb-8ec463d29672","symbol":"ABT","name":"Abbott Laboratories","asset_type":"stock","exchange":"US","country":"US","currency":"USD","sector":"Health Care","industry":"Health Care Equipment","crypto_category":null,"coingecko_id":null,"is_active":true,"created_at":"2026-11-16T20:38:59.474331+00:00","updated_at":"2026-11-16T20:38:59.474331+00:00"},"latest_value_score":{"id":10,"asset_id":"4b339c77-1cdc-4fe8-b9bb-8ec463d29672","score_date":"2026-11-18","value_score":30.358223928571427,"value_component":30.358223928571427,"quality_component":59.49991466666666,"risk_component":84.1952,"valuation_status":"weak","quality_status":"neutral","risk_status":"strong","value_trap_flag":false,"margin_of_safety":null,"fair_value_low":null,"fair_value_mid":null,"fair_value_high":null,"score_breakdown":{"risk":{"leverage_score":0.945505,"liquidity_score":0.5458333333333334,"volatility_score":1.0},"value":{"pb_score":0.48918609999999996,"pe_score":0.0,"dividend_score":1.0,"ev_ebitda_score":0.1251428571428571},"quality":{"roe_score":0.45689994999999994,"growth_score":0.9666666666666667,"margin_score":0.48735},"raw_metrics":{"beta":0.537,"ev_ebitda":18.248,"forward_pe":17.636942,"net_margin":0.09747,"trailing_pe":39.070892,"current_ratio":1.455,"price_to_book":3.5540695,"debt_to_equity":60.899,"dividend_yield":2.41,"revenue_growth":0.145,"operating_margin":0.15648,"return_on_equity":0.09137999}},"created_at":"2026-11-18T08:00:38.907794+00:00"},"latest_ranking":{"id":"600b4a36-6525-4520-b1ef-8a4662ad7c1c","asset_id":"4b339c77-1cdc-4fe8-b9bb-8ec463d29672","ranking_date":"2026-11-18","overall_score":46.79316584523809,"value_component":30.358223928571427,"quality_component":59.49991466666666,"risk_component":15.8048,"technical_component":72.2,"news_component":60.0,"opportunity_type":"watchlist","rank":82,"rationale":{"news_bias":0.23529411764705888,"technical":"Signal: add, confidence: 54.0","asset_type":"stock","components":{"news_component":60.0,"risk_component":15.8048,"value_component":30.358223928571427,"quality_component":59.49991466666666,"technical_component":72.2,"value_trap_penalty_applied":false},"news_strength":0.8499999999999999,"value_trap_flag":false,"articles_analyzed":10},"created_at":"2026-11-18T08:06:22.527111+00:00","updated_at":"2026-11-18T08:06:22.527111+00:00"},"latest_signal":{"id":"edfb1fb9-81dc-4eb0-876d-5845808f56d3","asset_id":"4b339c77-1cdc-4fe8-b9bb-8ec463d29672","signal_date":"2026-11-18T07:56:37.344086+00:00","signal_type":"tactical","action":"add","confidence":54.0,"entry_price":104.70999908447266,"entry_zone_low":101.57642691476005,"entry_zone_high":107.84357125418526,"stop_loss":98.44285474504743,"target_1":110.97714342389789,"target_2":114.1107155936105,"risk_reward_ratio":1.0,"position_size_pct":2.0,"time_horizon":"days_to_weeks","invalidation_level":98.44285474504743,"summary":"Fused signal based on technical setup and 10 recent news articles. News bias: 0.24, news strength: 0.85.","status":"active","created_at":"2026-11-18T07:06:14.880389+00:00","updated_at":"2026-11-18T07:56:37.344126+00:00","engine_version":null,"price_as_of":null,"price_fetched_at":null,"price_basis":null,"reference_price":null,"technical_score":null,"calculation_metadata":null},"signal_reasons":[{"id":89,"signal_id":"edfb1fb9-81dc-4eb0-876d-5845808f56d3","category":"news","reason":"Positive recent news supports the existing technical setup | High news impact detected | Technical confidence: 50.00 | News bias: 0.24 | News strength: 0.85 | Fused confidence: 54.00 | Recent articles analyzed: 10 | Previous technical action: hold","impact":"positive","weight":1.0,"source":"Finnhub news ingestion; 10 articles analyzed","created_at":"2026-11-18T07:56:37.649818+00:00"}],"recent_news":[{"id":14,"asset_id":"4b339c77-1cdc-4fe8-b9bb-8ec463d29672","published_at":"2026-11-17T20:08:42+00:00","title":"Abbott (ABT) Stock May Be 28% Undervalued Despite AI Testing Expansion","url":"https://finnhub.io/api/news?id=1611fa1ff853758f2a63539aebae6b8f038c238922a0c456fc831c7c76a13b3a","source":"Yahoo","category":"company_news","sentiment":0.3333333333333333,"impact_score":1,"relevance_score":1.0,"summary":"Abbott Laboratories has seen its share price under pressure over the past year, which puts fresh attention on what investors are really paying for in terms of its future cash flows. With the stock closing at US$107.45 most recently, the key issue is how that market tag lines up with what the business can generate in hard cash over time. The share price has fallen 15.3% over the past year, so the market is already repricing Abbott Laboratories and raising the question of whether its current...","created_at":"2026-11-18T07:12:10.909015+00:00"},{"id":15,"asset_id":"4b339c77-1cdc-4fe8-b9bb-8ec463d29672","published_at":"2026-11-17T17:38:01+00:00","title":"How Long Can HeartFlow Keep Burning Cash?","url":"https://finnhub.io/api/news?id=1b25300a1c620d105e338b2ac224dffad35b78ec4a07e32bfa3ec1d414d9e699","source":"Yahoo","category":"company_news","sentiment":0.0,"impact_score":0,"relevance_score":1.0,"summary":"Today's big story: Could Nvidia Stock Fall 50%? Follow The Cash.","created_at":"2026-11-18T07:12:11.008551+00:00"},{"id":16,"asset_id":"4b339c77-1cdc-4fe8-b9bb-8ec463d29672","published_at":"2026-11-17T08:56:10+00:00","title":"Ken Griffin Dumps SpaceX, Amazon; Buys ARKK and Bets Big on Marvell","url":"https://finnhub.io/api/news?id=e8e147d3b9f34ab801716761f85dc784539038aa03e5113eeb32711e2b6af640","source":"Benzinga","category":"company_news","sentiment":0.3333333333333333,"impact_score":1,"relevance_score":1.0,"summary":"Inside Citadel&#39;s Q3 13F: Ken Griffin slashed AMD and Amazon, raised Marvell 729%, and quietly unwound Leopold Aschenbrenner&#39;s AI fund.","created_at":"2026-11-18T07:12:11.107904+00:00"},{"id":17,"asset_id":"4b339c77-1cdc-4fe8-b9bb-8ec463d29672","published_at":"2026-11-16T22:36:40+00:00","title":"The Winners Inside SCHD - November 2026","url":"https://finnhub.io/api/news?id=c073735c337135254275f5275d9ff4c0cb3f56e0208a335369f819a0db8f5c97","source":"SeekingAlpha","category":"company_news","sentiment":0.0,"impact_score":0,"relevance_score":1.0,"summary":"The bull case for SCHD: 34 holdings screen at least 10% undervalued, with expected long-term returns above 10%; its YTD lead over SPY tops 20%.","created_at":"2026-11-18T07:12:11.212467+00:00"},{"id":18,"asset_id":"4b339c77-1cdc-4fe8-b9bb-8ec463d29672","published_at":"2026-11-16T17:47:22+00:00","title":"Is A Medicare Delay The Biggest Risk For DexCom Stock?","url":"https://finnhub.io/api/news?id=041be9c42479401db7ed4bee9d158f38527197ddaa6fc0c723aec524d32564c8","source":"Yahoo","category":"company_news","sentiment":-0.6666666666666666,"impact_score":2,"relevance_score":1.0,"summary":"DexCom (DXCM) owners have one dated question left for 2026: will Medicare agree to pay for glucose monitors for people with type 2 diabetes who are not on insulin? DexCom said on its call after Q3 results that it expects CMS to announce that coverage decision this year, with DexCom's current plan assuming coverage takes effect in the middle of 2027. By the close on Friday, Nov 13, no DexCom release had reported a coverage decision; its latest release before the close, on Nov 10, was about an upc","created_at":"2026-11-18T07:12:11.315829+00:00"},{"id":19,"asset_id":"4b339c77-1cdc-4fe8-b9bb-8ec463d29672","published_at":"2026-11-16T17:45:00+00:00","title":"Non-Animal Alternative Testing - Global Strategic Business Report 2026: Capitalize on 13.3% CAGR and $4.7B by 2032 as Abbott, Charles River, Emulate, Evotec, and Bio-Rad Reshape Testing","url":"https://finnhub.io/api/news?id=f94d494245febb20eda3bb123c6668d5c881e471909ccf546ed0963d9da570e3","source":"Yahoo","category":"company_news","sentiment":-0.3333333333333333,"impact_score":1,"relevance_score":1.0,"summary":"Cut research costs and speed development with AI toxicology, organ-on-chip and in vitro testing while improving human relevance, compliance and cruelty-free appeal.Dublin, Nov. 16, 2026 (GLOBE NEWSWIRE) -- \"Non-animal Alternative Testing - Global Strategic Business Report 2026\" has been added to ResearchAndMarkets.com's offering. Global Non-Animal Alternative Testing Market to Reach US$4.7 Billion by 2032 The global non-animal alternative testing market was valued at US$2 billion in 2025 and is","created_at":"2026-11-18T07:12:11.432322+00:00"},{"id":20,"asset_id":"4b339c77-1cdc-4fe8-b9bb-8ec463d29672","published_at":"2026-11-16T17:27:00+00:00","title":"Global Point of Care (POC) Immunoassay Analyzer Expansion Market 2026 | Capture 8.8% CAGR to 2030 as Roche, Abbott, Siemens Healthineers and Danaher Scale AI-Enabled POC Testing","url":"https://finnhub.io/api/news?id=7a5be0e38962e65db947ba1227636fd2bdb15130f3e558bf2c78c2e1ffc7539c","source":"Yahoo","category":"company_news","sentiment":1.0,"impact_score":3,"relevance_score":1.0,"summary":"Boost ROI via portable multiplex analyzers, AI and wireless connectivity, at-home testing, recurring service revenue, and acquisitions that expand decentralized diagnostics.Dublin, Nov. 16, 2026 (GLOBE NEWSWIRE) -- \"Point of Care (POC) Immunoassay Analyzer Expansion Market Report 2026\" has been added to ResearchAndMarkets.com's offering. The global point-of-care (POC) immunoassay analyzer expansion market is experiencing strong growth as healthcare providers increase their use of rapid, decentra","created_at":"2026-11-18T07:12:11.538954+00:00"},{"id":21,"asset_id":"4b339c77-1cdc-4fe8-b9bb-8ec463d29672","published_at":"2026-11-16T16:21:29+00:00","title":"Abbott Laboratories Extends Change in Control Agreements to December 31, 2028","url":"https://finnhub.io/api/news?id=e414036118e284520013f143fbb8abf1de43bf613214a12638a959e15a490dd5","source":"Fintel","category":"company_news","sentiment":0.0,"impact_score":0,"relevance_score":1.0,"summary":"","created_at":"2026-11-18T07:12:11.645748+00:00"},{"id":22,"asset_id":"4b339c77-1cdc-4fe8-b9bb-8ec463d29672","published_at":"2026-11-16T13:50:00+00:00","title":"Here's How Abbott's EP Business Is Shaping Up for the Rest of 2026","url":"https://finnhub.io/api/news?id=66f9d34f3516955ba8e074f1d3ad0fdd29e5f9a4599e98bef9b540c805b95b59","source":"Yahoo","category":"company_news","sentiment":0.0,"impact_score":0,"relevance_score":1.0,"summary":"ABT's EP business gains momentum as Volt adoption accelerates and new device launches expand its portfolio despite LAA market weakness.","created_at":"2026-11-18T07:12:11.761925+00:00"},{"id":23,"asset_id":"4b339c77-1cdc-4fe8-b9bb-8ec463d29672","published_at":"2026-11-16T13:42:12+00:00","title":"Should You Buy Neurocrine Biosciences Stock For Its Cash?","url":"https://finnhub.io/api/news?id=8818fffd39e254458ca4e79b74d7c13a5aab0af454c98d94f5b394981b700b6e","source":"Yahoo","category":"company_news","sentiment":0.0,"impact_score":0,"relevance_score":1.0,"summary":"For questions about this article or underlying research, email help@trefis.com.","created_at":"2026-11-18T07:12:11.871954+00:00"}]}